Rimonabant Reduced Spinal Glial Reactivity Without Reducing Morphine Tolerance in Rats

Ultra-low-dose rimonabant reduced morphine-associated spinal glial markers in rats but did not attenuate antinociceptive tolerance. The mismatch shows why a biomarker improvement cannot automatically stand in for a behavioral benefit.

Two receptor systems were compared

Male rats received daily morphine with ultra-low doses of alpha2-adrenergic antagonists or the CB1 antagonist rimonabant. Tail-flick responses were followed over seven days, and spinal tissue was examined on day eight. Drug-only controls helped separate combination effects from the antagonist exposure alone.

The behavioral and tissue results separated

Both tested alpha2 antagonists attenuated tolerance, while rimonabant did not. Nevertheless, rimonabant and one alpha2 antagonist reduced microglial reactivity and astrogliosis in the spinal dorsal horn. Thus, less glial-marker reactivity did not necessarily produce less tolerance in this comparison.

A shared label did not imply a shared mechanism

Ultra-low antagonist effects across receptor systems were a research motivation, not proof that every antagonist behaves alike. The findings argue against treating spinal glia as the sole explanation for the observed modulation of tolerance. They do not exclude glial contributions under other conditions.

The study's clearest lesson is evidentiary: report the behavioral null alongside the tissue change. It does not establish a cannabis-based method of preserving opioid analgesia, and an ultra-low research dose cannot be converted into a human regimen from this experiment.

Related: interpreting cannabis tolerance claims.

Research cited

Grenier P; Wiercigroch D; Olmstead MC; Cahill CM. Dissociation between morphine-induced spinal gliosis and analgesic tolerance by ultra-low-dose α2-adrenergic and cannabinoid CB1-receptor antagonists. Behavioural pharmacology (2018). doi:10.1097/FBP.0000000000000377. Findings discussed from the study abstract.